Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB00
Post# of 341
(Total Views: 216)
Posted On: 04/18/2022 3:51:35 PM
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CYB004 Pipeline Program Receives Key Patent Approval from WIPO
- World Intellectual Property Organization has published CYBN’s international patent application
- Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options
- Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds
Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled “Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods,” further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs.
The application covers an array of inhalation delivery methods across multiple psychedelic molecules. The WIPO’s recent move allows Cybin to pursue patent applications and seek protection for multiple inhaled forms of psychedelic molecules that are currently being researched and developed. The application also covers future developments made by the company.
“The publication of this PCT patent application demonstrates our continued commitment to discovering and developing new psychedelic-based treatment options, in addition to identifying and combining potentially improved and well-controlled delivery systems with these clinical candidates,” said Cybin CEO Doug Drysdale. “In addition, our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation, which is aimed at overcoming some of the known challenges of oral and IV-administered DMT.”
Earlier this year, Cybin announced another key milestone for its CYB004 investigational deuterated dimethyltryptamine (“DMT”) compound. In February, the U.S. Patent and Trademark Office granted a patent for CYB004 (https://nnw.fm/Oldt7) that covers composition of matter and protects the proprietary drug substance as a putative new chemical entity.
“From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of classical psychedelics, while addressing the known limitations necessary for these molecules to become approvable therapeutics,” said Drysdale. “We are extremely pleased to receive a composition of matter patent for CYB004, adding strong protection for our growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments that we are making in our CYB004 program. This patent is both rewarding and timely as we prepare to initiate a pilot study for CYB004 in the third quarter of 2022 and work tirelessly to develop an important and alternative treatment option for the millions of people suffering from anxiety disorders.”
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company focuses on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- World Intellectual Property Organization has published CYBN’s international patent application
- Publication of patent application demonstrates CYBN’s continued commitment to discovering, developing psychedelic-based treatment options
- Company continues to see strong protection for growing intellectual property portfolio of psychedelic-based compounds
Cybin (NEO: CYBN) (NYSE American: CYBN) announced that the World Intellectual Property Organization (“WIPO”) has published an international patent application filed by Cybin. According to Cybin, the application, titled “Methods for Delivery of Psychedelic Medications by Inhalation and Systems for Performing the Methods,” further strengthens Cybin’s long-term intellectual property (“IP”) position related to psychedelic-based programs.
The application covers an array of inhalation delivery methods across multiple psychedelic molecules. The WIPO’s recent move allows Cybin to pursue patent applications and seek protection for multiple inhaled forms of psychedelic molecules that are currently being researched and developed. The application also covers future developments made by the company.
“The publication of this PCT patent application demonstrates our continued commitment to discovering and developing new psychedelic-based treatment options, in addition to identifying and combining potentially improved and well-controlled delivery systems with these clinical candidates,” said Cybin CEO Doug Drysdale. “In addition, our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation, which is aimed at overcoming some of the known challenges of oral and IV-administered DMT.”
Earlier this year, Cybin announced another key milestone for its CYB004 investigational deuterated dimethyltryptamine (“DMT”) compound. In February, the U.S. Patent and Trademark Office granted a patent for CYB004 (https://nnw.fm/Oldt7) that covers composition of matter and protects the proprietary drug substance as a putative new chemical entity.
“From the outset, Cybin has focused on creating differentiated compounds that harness the potential efficacy of classical psychedelics, while addressing the known limitations necessary for these molecules to become approvable therapeutics,” said Drysdale. “We are extremely pleased to receive a composition of matter patent for CYB004, adding strong protection for our growing intellectual property portfolio of psychedelic-based compounds, supporting and protecting the investments that we are making in our CYB004 program. This patent is both rewarding and timely as we prepare to initiate a pilot study for CYB004 in the third quarter of 2022 and work tirelessly to develop an important and alternative treatment option for the millions of people suffering from anxiety disorders.”
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. The company focuses on progressing psychedelics to therapeutics by engineering proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for mental health disorders.
For more information, visit the company’s website at www.Cybin.com.
NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)